Schistosoma mansoni infection among preschool age children attending Erer Health Center, Ethiopia and the response rate to praziquantel

Objective Preschool age children (PSAC) are excluded from community based praziquantel treatment programs mainly due to paucity of evidence on the magnitude of schistosomiasis, efficacy and safety of this treatment in PSAC. The aim of this study is to assess Schistosoma mansoni infection rate and evaluate response to praziquantel in PSAC. A facility based longitudinal study was employed from April to June 2016 at Erer Health Center, Eastern Ethiopia. Stool sample was examined for schistosomiasis in 236 PSAC and repeated after 4 weeks post-treatment in positive individuals. Treatment outcomes were recorded and interpreted. Results Out of the 236 study participants, 59 (25%) were infected with S. mansoni. Praziquantel treatment (40 mg/kg) resulted in 96.4% cure rate and 99.4% egg reduction rate. Children of 3–5 year old were significantly affected with S. mansoni infection. Nausea and fatigue were common mild adverse events within 4 h of treatment however moderate and severe adverse events and allergic reactions were not observed. In conclusion, praziquantel at 40 mg/kg, the dose utilized in standard care for school age children, is tolerable and efficacious in the treatment of S. mansoni infection in PSAC, which calls for the healthcare system to provide appropriate service for this population. Electronic supplementary material The online version of this article (10.1186/s13104-019-4246-8) contains supplementary material, which is available to authorized users.


Introduction
Schistosomiasis is one of the most common parasitic diseases in many parts of Ethiopia, usually at an altitude between 1200 and 2000 m above sea level [1]. The anthelmintic drug praziquantel is the cornerstone for morbidity control with millions of people treated every year [2,3]. It has been a drug of choice for schistosomiasis control for more than 40 years [4]. However, preschool age children (PSAC) are currently excluded from preventive chemotherapy control campaigns. The reasons for this exclusion include: PSAC to be considered at low risk of infection, insufficiency of evidence in safety and efficacy of praziquantel for this age group [5] and lack of a pediatric formulation [6]. Recently, there is growing of evidence of infection in infants and young children in different parts of sub-Saharan African countries [7]. For instance a community based cross-sectional study in Northwest Ethiopia showed that 11.2% of PSAC are infected with S. mansonia [8]. The reported disease burden in this specific age group raise a concern of how the existing standard treatment of school aged children is extended to PSAC in high risk areas with the optimized dose of praziquantel.
Many studies showed that treatment with praziquantel is tolerable and efficacious in school age children (SAC) for the treatment of schistosomiasis [9]. Due to the limited evidence on the safety for children under 5 years of age at the moment, preventive chemotherapy for schistosomiasis is not indicated for this age group in many countries [10]. Although PSAC may also be at risk of schistosomiasis similar to SAC and can be infected very early in childhood, to authors' knowledge the efficacy and tolerability for praziquantel in the treatment of Schistosoma mansoni infection in young children in Ethiopia was not assessed. So, this study was aimed to assess S. mansoni infection in PSAC and the response rate for praziquantel treatment (40 mg/kg).

Study design
A facility based longitudinal study was employed. A facility based screening and follow-up were arranged to ensure that the PSAC, minor study participants, are under proper standard care.

Study site and study population
The study was conducted at Erer Woreda Health Center, Shinile Zone of Somali Region, Ethiopia from April to June 2016 having catchment population of 77,628 at Erer district according to national census in 2007 [11]. The average elevation of this district is 824 meters above sea level [12]. In this district, more than 89.6% of housing units get drinking water from well, spring, river and lake. River is one of the main source of drinking water with easy access to children main [11].
All PSAC who visited Erer Health Center for different medical reasons during the study period were included. A total of 236 children were screened for S. mansoni eggs. Those participants who are positive for the test were treated with praziquantel 40 mg/kg and followed for a month to assess the treatment outcome.

Inclusion and exclusion criteria
Inclusion criteria PSAC less than 6 years of age, whose parents gave written informed consent for the study.
Exclusion criteria PSAC who were treated with praziquantel within a month time of study recruitment period.

Data collection techniques and clinical assessments
All demographic and clinical information were recorded on a standard record form. Interviews were conducted by nurses at the Health Center. Information on health condition of children and adverse events after treatment were included in the interview. Mothers/guardians of children were interviewed at 4 and 24 h post treatment to assess tolerability of praziquantel.

Stool sample collection and laboratory procedures
Stool samples were collected initially once per day for two consecutive days and on day 28 and day 29 for reassessment to evaluate drug response. Parasitological diagnosis of S. mansoni was performed using double Kato-Katz thick smears preparation at the Health Center Laboratory. The number of S. mansoni eggs were counted and recorded.

Dosing and treatment procedure
Children with positive stool examination for S. mansoni who were treated with the standard single dose praziquantel prepared by trained nurses according to weight-based guideline (40 mg/kg) were considered for follow-up. At each supervised drug administration by the health care providers, children were observed for 30 min.

Follow-up procedures
Children who were enrolled in the study and treated with single dose of praziquantel were appointed for clinical assessments. Evaluations of adverse events were performed with parent/guardian report using standard list of praziquantel related adverse events at 4 and 24 h posttreatment follow-up. Stool examination was performed to determine egg reduction rate (ERR) and cure rate (CR) of praziquantel using the following formulas:

Statistical analysis
Data were recorded on standardized record forms and double entered to EPI data 3.1 and exported to SPSS software version 20 for analysis. Descriptive statistics were calculated for variables and bivariate analysis was conducted to check statistically significant association between variables. Geometric mean egg counts were calculated for participants who are positive for S. mansoni. It was categorized into infection intensities: light infections, 1-99 epg, moderate infections: 100-399 epg; and heavy infections: > 400 epg according to WHO guidelines [10].

Cure rate and egg reduction rate
Cure rate after treatment was calculated as the percentages of individuals who were tested as S. mansoni egg free after treatment. The CR and the ERR were 96.4% and 99.42% respectively.  Table S1).

Discussion
In the present study, prevalence of S. mansoni egg positivity among PSAC attending Erer Health center was 25%. A cure rate of 96.4% was achieved by treating the PSAC that were found positive for schistosomiasis with the standard care intervention, praziquantel 40 mg/kg. The egg reduction rate was 99.42%. The institution based prevalence of S. mansoni among PSAC was 25%. This finding is similar to reports from cross-sectional survey conducted in Azaguie district of Côte d'Ivoire where the prevalence of S. mansoni among PSAC was 21.6% (n = 160) [13]. The prevalence of S. mansoni egg positivity in Hamad Alla village, Sudan was 44.3% (n = 106) [14] and in Uganda studied in 7 lakeshore villages on 5 months to 7 year-old children was 37.7% (n = 979) [15]. From a targeted epidemiological survey in Uganda, egg positivity rate was found to be 44.3% (n = 131) at Lake Albert and 16% (n = 232) at Lake Victroria areas [16]. A cross sectional household based study conducted in Wondo Genet, Southern Ethiopia reveals that 37.2% of S. mansoni infection in under-five children [17]. The difference in rate of positivity among the reports might be due to difference in sampling population, study design and geographical settings.
The present study showed that children at the age of five were more likely infected with S. mansoni compared to lower age groups. A similar study conducted in Ugandan PSAC showed that children aged between 3 and 6 years had higher risk of infection than their younger counterparts [16]. This might be due to high frequency of water body contact with the aforementioned age groups. The current study shows that children who were often taken to river during fetching water were three times more likely infected with S. mansoni compared to those not taken at all.
In the current study praziquantel achieved CR of 96.4% against S. mansoni infections 4 weeks after treatment among PSAC. Cure rate of this study was higher than that of study conducted in Uganda 77.6% [15], study in districts of Côte d'Ivoire 88.6% [5] and Sudan 90.5% [14].